Farmas USA

Joer, segunda sesion del año y no se que pasa que no compro na de na ....  ains ...

EUR/USD

Salvo IBB +1% ( y gracias a las Big ) ... el resto de los indices no levantan ni medio palmo ...

Study Opens New Doors for ALS Drug Discovery

http://neurosciencenews.com/als-sod1-neurology-genetics-3331/

Posible bandera bajista en progreso

velas 5 min, ya veremos ...

IBB

edito: rompio pa'bajo

bueno , bueno ... AMRN 1,76 repite casi minimos de ayer y patadon de +10 centavos que para esta pajara eso es mucho

MNKD

MannKind Perilously Close to Bankruptcy After Sanofi Exit del Bastardo

The company is short on cash, deeply in debt and has no established infrastructure to sell Afrezza.

The most likely end game for MannKind is bankruptcy. If the company is lucky, the Afrezza assets could be picked up by an opportunistic acquirer for pennies on the dollar. Even if that rosy scenario unfolds, MannKind's creditors will receive the proceeds. Equity holders will be left with nothing.

MannKind owed Sanofi $44 million at the end of the third quarter under the cost-sharing arrangement for the Afrezza partnership. The company's Sanofi debt is already larger and must be repaid unless Sanofi offers loan forgiveness as a going-away present. Even then, MannKind maintains significant debt on its books held by Deerfield Capital Management.

MannKind's effort to raise more money to sell Afrezza on its own -- or find another partner willing to do so -- will also be complicated by fixed spending requirements. Most notably, the FDA is requiring MannKind to conduct a five-year, 8,000-patient lung safety study of Afrezza. This study, not yet started, was to be funded by Sanofi.

The company can tap an existing At-The-Money equity financing facility for additional cash and founder Al Mann can also lend the company $30 million

http://bit.ly/1TCdwEd

ALNY, sigue la construcción del segundo hombro...
A ver si lo cierra y se va a máximos este año....

ALNY